Intratumoral expression of genes encoding Cytochrome P450 enzymes (CYP) might play a critical role not only in cancer development but also in the metabolism of anticancer drugs. The purpose of this study was to compare the mRNA expression patterns of seven representative CYPs in paired tumor and normal tissue of child patients with rabdomyosarcoma (RMS). Using real time quantitative RT-PCR, the gene expression pattern of CYP1A1, CYP1A2, CYP1B1, CYP2E1, CYP2W1, CYP3A4, and CYP3A5 were analyzed in tumor and adjacent non-tumor tissues from 13 child RMS patients. Protein concentration of CYPs was determined using Western blot. The expression levels were tested for correlation with the clinical and pathological data of the patients. Our data showed that the expression levels of CYP1A1 and CYP1A2 were negligible. Elevated expression of CYP1B1 mRNA and protein was detected in most RMS tumors and adjacent normal tissues. Most cancerous samples exhibit higher levels of both CYP3A4 and CYP3A5 compared with normal tissue samples. Expression of CYP2E1 mRNA was found to be significantly higher in tumor tissue, however no relation was found with protein levels. CYP2W1 mRNA and/or protein are mainly expressed in tumors. In conclusion, we defined the CYP gene expression profile in tumor and paired normal tissue of child patients with RMS. The overexpression of CYP2W1, CYP3A4 and CYP3A5 in tumor tissues suggests that they may be involved in RMS chemoresistance; furthermore, they may be exploited for the localized activation of anticancer prodrugs.
References
[1]
Saab R, Spunt SL, Skapek SX (2011) Myogenesis and rhabdomyosarcoma the Jekyll and Hyde of skeletal muscle. Curr Top Dev Biol 94: 197–234. doi: 10.1016/b978-0-12-380916-2.00007-3
[2]
Wang C (2012) Childhood rhabdomyosarcoma: recent advances and prospective views. J Dent Res 91: 341–350. doi: 10.1177/0022034511421490
[3]
Grufferman S, Wang HH, DeLong ER, Kimm SY, Delzell ES, et al. (1982) Environmental factors in the etiology of rhabdomyosarcoma in childhood. J Natl Cancer Inst 68: 107–113.
[4]
Hartley AL, Birch JM, McKinney PA, Teare MD, Blair V, et al. (1988) The Inter-Regional Epidemiological Study of Childhood Cancer (IRESCC): case control study of children with bone and soft tissue sarcomas. Br J Cancer 58: 838–842. doi: 10.3109/02688699009000677
[5]
Pappo AS, Shapiro DN, Crist WM, Maurer HM (1995) Biology and therapy of pediatric rhabdomyosarcoma. J Clin Oncol 13: 2123–2139.
[6]
Melguizo C, Prados J, Rama AR, Ortiz R, álvarez PJ, Fernández JE, et al. (2001) Multidrug resistance and rhabdomyosarcoma. Oncol Rep 26: 755–761.
[7]
Cocker HA, Tiffin N, Pritchard-Jones K, Pinkerton CR, Kelland LR (2001) In vitro prevention of the emergence of multidrug resistance in a pediatric rhabdomyosarcoma cell line. Clin Cancer Res 7: 3193–3198.
[8]
McFadyen MC, Melvin WT, Murray GI (2004) Cytochrome P450 enzymes: novel options for cancer therapeutics. Mol Cancer Ther 3: 363–371.
[9]
Oyama T, Kagawa N, Kunugita N, Kitagawa K, Ogawa M, et al. (2004) Expression of cytochrome P450 in tumor tissues and its association with cancer development. Front Biosci 19: 1967–1976. doi: 10.2741/1378
[10]
Nebert DW, Russell DW (2002) Clinical importance of the cytochromes P450. Lancet 360: 1155–1162. doi: 10.1016/s0140-6736(02)11203-7
[11]
Pavek P, Dvorak Z (2008) Xenobiotic-induced transcriptional regulation of xenobiotic metabolizing enzymes of the cytochrome P450 superfamily in human extrahepatic tissues. Curr Drug Metab 9: 129–143. doi: 10.2174/138920008783571774
[12]
Ding X, Kaminsky LS (2003) Human extrahepatic cytochromes P450: function in xenobiotic metabolism and tissue-selective chemical toxicity in the respiratory and gastrointestinal tracts. Annu Rev Pharmacol Toxicol 43: 149–173. doi: 10.1146/annurev.pharmtox.43.100901.140251
[13]
Rodriguez AC, Ingelman SM (2006) Cytochrome P450 pharmacogenetics and cancer. Oncogene 25: 1679–1691. doi: 10.1038/sj.onc.1209377
[14]
Weiss AR, Lyden ER, Anderson JR, Hawkins DS, Spunt SL, et al. (2013) Histologic and clinical characteristics can guide staging evaluations for children and adolescents with rhabdomyosarcoma: a report from the Children’s Oncology Group Soft Tissue Sarcoma Committee. J Clin Oncol 31: 3226–32. doi: 10.1200/jco.2012.44.6476
[15]
Androutsopoulos VP, Tsatsakis AM, Spandidos DA (2009) Cytochrome P450 CYP1A1: wider roles in cancer progression and prevention. BMC Cancer 9: 187–203. doi: 10.1186/1471-2407-9-187
[16]
Hankinson O (1995) The aryl hydrocarbon receptor complex. Annu Rev Pharmacol Toxicol 35: 307–340. doi: 10.1146/annurev.pa.35.040195.001515
[17]
Molina OD, González ZJF, Camacho CR, López AO, Colin MO, et al. (2013) Xenobiotic-Metabolizing Enzymes in Skeletal Muscle of Children and Adolescents. Pharmacology & Pharmacy 4: 231–239. doi: 10.4236/pp.2013.42032
[18]
Murray GI, Taylor MC, McFadyen MC, McKay JA, Greenlee WF, et al. (1997) Tumor-specific expression of cytochrome P450 CYP1B1. Cancer Res 57: 3026–3031.
[19]
Murray GI, Melvin WT, Greenlee WF, Burke MD (2001) Regulation, function, and tissue-specific expression of cytochrome P450 CYP1B1. Annu Rev Pharmacol Toxicol 41: 297–316. doi: 10.1146/annurev.pharmtox.41.1.297
[20]
Rochat B, Morsman JM, Murray GI, Figg WD, McLeod HL (2001) Human CYP1B1 and anticancer agent metabolism: mechanism for tumor-specific drug inactivation?. J Pharmacol Exp Ther 296: 537–41.
[21]
Potter GA, Patterson LH, Wanogho E, Perry PJ, Butler PC, et al. (2002) The cancer preventative agent resveratrol is converted to the anticancer agent piceatannol by the cytochrome P450 enzyme CYP1B1. Br J Cancer 86: 774–778.
[22]
Bergheim I, Bode C, Parlesak A (2005) Decreased expression of cytochrome P450 protein in non-malignant colonic tissue of patients with colonic adenoma. BMC Gastroenterol 5: 34–44.
[23]
Kocarek TA, Zangar RC, Novak RF (2000) Post-transcriptional regulation of rat CYP2E1 expression: role of CYP2E1 mRNA untranslated regions in control of translational efficiency and message stability. Arch Biochem Biophys 376: 180–190. doi: 10.1006/abbi.2000.1704
[24]
Tanaka E, Terada M, Misawa S (2000) Cytochrome P450 2E1: its clinical and toxicological role. J Clin Pharm Ther 25: 165–175. doi: 10.1046/j.1365-2710.2000.00282.x
[25]
Karlgren M, Miura S, Ingelman-Sundberg M (2005) Novel extrahepatic cytochrome P450s. Toxicol Appl Pharmacol 207: 57–61. doi: 10.1016/j.taap.2004.12.022
[26]
Karlgren M, Ingelman-Sundberg M (2007) Tumour-specific expression of CYP2W1: its potential as a drug target in cancer therapy. Expert Opin Ther Targets 11: 61–67. doi: 10.1517/14728222.11.1.61
[27]
Gomez A, Karlgren M, Edler D, Bernal ML, Mkrtchian S, et al. (2007) Expression of CYP2W1 in colon tumors: regulation by gene methylation. Pharmacogenomics 8: 1315–1325. doi: 10.2217/14622416.8.10.1315
[28]
Trédan O, Garbens AB, Lalani AS, Tannock IF (2009) The hypoxia-activated ProDrug AQ4N penetrates deeply in tumor tissues and complements the limited distribution of mitoxantrone. Cancer Res 69: 940–947. doi: 10.1158/0008-5472.can-08-0676
[29]
Dhaini HR, Thomas DG, Giordano TJ, Johnson TD, Biermann JS, et al. (2003) Cytochrome P450 CYP3A4/5 expression as a biomarker of outcome in osteosarcoma. J Clin Oncol 21: 2481–2485. doi: 10.1200/jco.2003.06.015
[30]
Mir O, Ropert S, Alexandre J, Goldwasser F, Treluyer JM (2007) CYP3A4/5 and pharmacogenetics in patients with sarcoma. Lancet Oncol 8: 667–668. doi: 10.1016/s1470-2045(07)70215-2
[31]
Chang TK, Weber GF, Crespi CL, Waxman DJ (1993) Differential activation of cyclophosphamide and ifosphamide by cytochromes P-450 2B and 3A in human liver microsomes. Cancer Res 53: 5629–5637.
[32]
Martínez C, García-Martín E, Pizarro RM, García-Gamito FJ, Agúndez JA (2002) Expression of paclitaxel-inactivating CYP3A activity in human colorectal cancer: implications for drug therapy. Br J Cancer 87: 681–686.
